Trinity Biotech (TRIB) EBIAT (2016 - 2024)
Historic EBIAT for Trinity Biotech (TRIB) over the last 16 years, with Q4 2024 value amounting to -$17.0 million.
- Trinity Biotech's EBIAT fell 20816.07% to -$17.0 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$31.9 million, marking a year-over-year increase of 1428.3%. This contributed to the annual value of -$31.2 million for FY2024, which is 2996.92% down from last year.
- According to the latest figures from Q4 2024, Trinity Biotech's EBIAT is -$17.0 million, which was down 20816.07% from -$4.8 million recorded in Q3 2024.
- Trinity Biotech's 5-year EBIAT high stood at $7.3 million for Q3 2020, and its period low was -$18.6 million during Q2 2023.
- Its 5-year average for EBIAT is -$4.9 million, with a median of -$5.2 million in 2023.
- As far as peak fluctuations go, Trinity Biotech's EBIAT skyrocketed by 16377.39% in 2020, and later tumbled by 19166797.86% in 2023.
- Quarter analysis of 5 years shows Trinity Biotech's EBIAT stood at -$9.6 million in 2020, then skyrocketed by 58.65% to -$4.0 million in 2021, then plummeted by 152.63% to -$10.1 million in 2022, then surged by 45.42% to -$5.5 million in 2023, then crashed by 208.16% to -$17.0 million in 2024.
- Its last three reported values are -$17.0 million in Q4 2024, -$4.8 million for Q3 2024, and -$6.9 million during Q2 2024.